Detalles de la búsqueda
1.
Real-world efficacy of sofosbuvir plus velpatasvir therapy for patients with hepatitis C virus-related decompensated cirrhosis.
Hepatol Res
; 50(11): 1234-1243, 2020 Nov.
Artículo
en Inglés
| MEDLINE | ID: mdl-32914512
2.
Eicosapentaenoic acid/arachidonic acid ratio as a possible link between non-alcoholic fatty liver disease and cardiovascular disease.
Hepatol Res
; 45(5): 533-9, 2015 May.
Artículo
en Inglés
| MEDLINE | ID: mdl-24976364
3.
Efficacy of probucol for the treatment of non-alcoholic steatohepatitis with dyslipidemia: An open-label pilot study.
Hepatol Res
; 44(4): 429-35, 2014 Apr.
Artículo
en Inglés
| MEDLINE | ID: mdl-23607264
4.
Postprandial insulin secretion pattern is associated with histological severity in non-alcoholic fatty liver disease patients without prior known diabetes mellitus.
J Gastroenterol Hepatol
; 26(3): 517-22, 2011 Mar.
Artículo
en Inglés
| MEDLINE | ID: mdl-21054523
5.
Hemobilia after laparoscopic cholecystectomy that was successfully treated conservatively: Case report.
Int J Surg Case Rep
; 77: 307-310, 2020.
Artículo
en Inglés
| MEDLINE | ID: mdl-33197773
6.
A nuclear receptor-mediated choleretic action of fibrates is associated with enhanced canalicular membrane fluidity and transporter activity mediating bile acid-independent bile secretion.
J Atheroscler Thromb
; 12(4): 211-7, 2005.
Artículo
en Inglés
| MEDLINE | ID: mdl-16141625
7.
Serum asymmetric dimethylarginine levels are independently associated with procollagen III N-terminal peptide in nonalcoholic fatty liver disease patients.
Clin Exp Med
; 14(1): 45-51, 2014 Feb.
Artículo
en Inglés
| MEDLINE | ID: mdl-23179302
8.
Atorvastatin improves disease activity of nonalcoholic steatohepatitis partly through its tumour necrosis factor-α-lowering property.
Dig Liver Dis
; 44(6): 492-6, 2012 Jun.
Artículo
en Inglés
| MEDLINE | ID: mdl-22265683
9.
Serum levels of pigment epithelium-derived factor (PEDF) are independently associated with procollagen III N-terminal peptide levels in patients with nonalcoholic fatty liver disease.
Clin Biochem
; 45(18): 1554-7, 2012 Dec.
Artículo
en Inglés
| MEDLINE | ID: mdl-22884488
10.
Increased insulinogenic index is an independent determinant of nonalcoholic fatty liver disease activity score in patients with normal glucose tolerance.
Dig Liver Dis
; 44(11): 935-9, 2012 Nov.
Artículo
en Inglés
| MEDLINE | ID: mdl-22809960
11.
Efficacy of rosuvastatin for the treatment of non-alcoholic steatohepatitis with dyslipidemia: An open-label, pilot study.
Hepatol Res
; 42(11): 1065-72, 2012 Nov.
Artículo
en Inglés
| MEDLINE | ID: mdl-22583925
12.
Atorvastatin decreases serum levels of advanced glycation endproducts (AGEs) in nonalcoholic steatohepatitis (NASH) patients with dyslipidemia: clinical usefulness of AGEs as a biomarker for the attenuation of NASH.
J Gastroenterol
; 45(7): 750-7, 2010 Jul.
Artículo
en Inglés
| MEDLINE | ID: mdl-20112031
13.
Efficacy of atorvastatin for the treatment of nonalcoholic steatohepatitis with dyslipidemia.
Metabolism
; 57(12): 1711-8, 2008 Dec.
Artículo
en Inglés
| MEDLINE | ID: mdl-19013295
14.
Elevated levels of serum advanced glycation end products in patients with non-alcoholic steatohepatitis.
J Gastroenterol Hepatol
; 22(7): 1112-9, 2007 Jul.
Artículo
en Inglés
| MEDLINE | ID: mdl-17559366
Resultados
1 -
14
de 14
1
Próxima >
>>